Cetrorelix vs Kisspeptin-54

Competitive GnRH receptor antagonist; immediately blocks pituitary GnRH receptors; rapidly suppresses LH/FSH without initial flare effect; used for controlled hormonal suppression

Cetrorelix is a synthetic GnRH antagonist peptide used in assisted reproductive technology (ART) to prevent premature luteinizing hormone (LH) surges during controlled ovarian stimulation protocols. By competitively blocking GnRH receptors in the pituitary gland, cetrorelix rapidly suppresses LH release without the initial hormonal flare seen with GnRH agonists, allowing more precise timing of oocyte retrieval. Clinical studies including randomized controlled trials have established cetrorelix as an effective option for LH surge prevention in IVF and ICSI cycles, with well-characterized safety and efficacy data across multiple formulations. Cetrorelix is an FDA-approved prescription medication (Cetrotide) indicated for use under specialist supervision in fertility treatment settings. Cetrorelix dosing protocols and IVF context In IVF, cetrorelix is used under two standard protocols. The multiple-dose protocol administers 0.25mg subcutaneously once daily starting from stimulation day 5 or 6, continuing until the day of oocyte trigger — this prevents LH surge during the follicular growth phase. The single-dose protocol administers 3mg once when the leading follicle reaches approximately 14mm, providing LH suppression for approximately 96 hours; a supplemental 0.25mg dose is added if trigger has not occurred by day 4. Both protocols have established efficacy data and are used depending on clinic preference and patient response characteristics. Cetrorelix vs ganirelix: Cetrorelix (Cetrotide) and ganirelix (Antagon, Orgalutran) are both GnRH receptor antagonists used in the same IVF indication. Both act as competitive antagonists at the pituitary GnRH receptor, producing rapid suppression without the initial LH flare seen with agonists. They are pharmacologically equivalent in mechanism; differences relate to proprietary formulation, dosing schedule in specific protocols, and market availability in different regions. Neither requires the weeks-long downregulation period that GnRH agonist protocols (triptorelin, leuprolide) involve — antagonist protocols can begin mid-stimulation, reducing the total cycle length. Cetrorelix and ganirelix are both prescription-only fertility medications requiring specialist reproductive endocrinology supervision.

Full-length kisspeptin (54 amino acids); binds KISS1R on GnRH neurons with higher receptor occupancy and longer duration than KP-10; induces more sustained GnRH/LH pulses

Kisspeptin-54 (Kp-54) is the primary full-length endogenous form of the KISS1-derived peptide family, a hypothalamic neuropeptide that acts as the central regulator of GnRH pulsatility and reproductive hormone signaling. As a KISS1R agonist, kisspeptin-54 directly stimulates GnRH neurons, initiating LH and FSH release from the pituitary and driving downstream gonadal steroidogenesis in both males and females. Published research documents kisspeptin-54 regulation of the reproductive axis across the menstrual cycle and its emerging potential as a treatment for sexual dysfunction, with studies suggesting effects on reproductive hormone output and libido-related pathways. Kisspeptin-54 is an investigational compound; it is not approved by the FDA for any clinical indication and its applications in sexual health and fertility remain under active investigation. Kisspeptin-54 vs kisspeptin-10: length and activity distinctions Kisspeptin-54 (Kp-54) is the full-length 54-amino-acid endogenous KISS1-derived peptide, while kisspeptin-10 (Kp-10) is the C-terminal decapeptide fragment responsible for KISS1R (GPR54) binding activity. Both isoforms activate the same receptor, but Kp-54 has a longer plasma half-life and sustained GnRH-stimulating activity relative to the shorter fragment, making it the preferred form for clinical research contexts where prolonged hormonal response is required. In research settings, Kp-10's lower cost and simpler synthesis has led to its wider use in mechanistic studies, while Kp-54 is preferred in clinical trials involving ovulation induction. Kisspeptin-54 in IVF: A published phase 2 clinical trial (Abbara et al., NEJM 2020) demonstrated that kisspeptin-54 could serve as an ovulation trigger in IVF — replacing the conventional hCG trigger in women at high risk of ovarian hyperstimulation syndrome (OHSS). The kisspeptin-54 trigger produced lower OHSS rates compared to hCG while maintaining acceptable oocyte yields, establishing it as a clinically relevant alternative trigger agent for high-risk patients. This application positions kisspeptin-54 within fertility medicine as a potential hCG substitute rather than just a mechanistic research tool. It remains investigational outside of trial contexts and is not currently approved by the FDA or EMA for ovulation induction.